The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage.
Antifibrinolytic drugs have been investigated in a series of 58 patients with recent aneurysmal subarachnoid hemorrhage. It is concluded that tranexamic acid (AMCA) provides a rational method for reducing the frequency of recurrences, and that antifibrinolytic treatment is a preliminary to surgical intervention. In the present series, ischemic complications, which often follow aneurysmal hemmorrhage, seem to be of a more serious nature. There is evidence also that hydrocephalus due to adhesive arachnoiditis is a rare occurrence. The last 20 patients of the present series have been treated with very low doses of AMCA associated with parotid kallikrein inhibitor (Trasylol); this dosage has been effective in preventing recurrence and has appeared to be freer from severe side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D006801:Humans; D002532:Intracranial Aneurysm / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D012422:Rupture, Spontaneous; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D000614:Aminocaproates; D003509:Cyclohexanecarboxylic Acids; D014148:Tranexamic Acid; D015119:Aminocaproic Acid